View Clinical Trial (Medical Research Study)
Computerized Cognitive Skills Training in Severe Mental Illness
| City: |
|
New York |
| State: |
|
New York |
| Zip Code: |
|
10605 |
| Conditions: |
|
Schizophrenia - Schizoaffective Disorder |
| Purpose: |
|
The study is designed to evaluate the effectiveness of computerized cognitive skills
training for improving memory and problem-solving skills in inpatients with schizophrenia.
|
| Study Summary: |
|
Subjects are stable inpatients and outpatients with schizophrenia or schizoaffective
disorder who are receiving atipsychotic medication at Manhattan Psychiatric Center.
Patients receive baseline assessments (MCCB-MATRICS; Personal and Social Performance Scale,
FEDT/FEIT and PANSS) and then are assigned to Cognitive Remediation (CRT) using the COGPACK
program, patients are then randomly assigned to a social cognition program (Mind Reader
Interactive Guide to Emotions) for a period of 12 weeks. Following 12 weeks of treatment in
either CRT + Mind Reader or CRT alone, assessments are repeated by raters.
Cognitive Remediation (CRT): CRT (COGPACK, Marker and Olbrich, 1998) consists of
computerized practice tests for seven cognitive domains. There are 64 programs for testing
and training, each with several variants for the domains of visuomotor skills,
comprehension, reaction, vigilance, memory, language, and intellectual skills. Exercises in
COGPACK can be edited and expanded. Patients attend 2 (45-minutes each) groups and 1
discussion group.
Social Cognition Training: Mind Reader (Baron-Cohen et al, 2004) is an interactive
computerized program of emotions and mental states. It is based on a taxonomic system of 412
emotions and mental states, grouped into 24 emotion groups, and six developmental levels
(from age 4 to adulthood). The emotions and mental states are organized systematically,
according to the emotion groups and developmental levels. Patients assigned to Mind Reader
attend 1 group per week.
Both the CRT and Mind Reader are administered in small groups of six to eight patients each.
|
| Criteria: |
|
Inclusion Criteria:
1. Age 18 and above;
2. In- and out-patients;
3. DSM-IV diagnosis of schizophrenia (all subtypes) or schizoaffective disorder with
illness duration >5 years;
4. Auditory and visual acuity adequate to complete cognitive tests;
5. Stable dose of oral atypical antipsychotic for at least 4 weeks;
6. Total PANSS score > 60;
7. Good physical health determined by physical examination from medical chart review;
8. Capacity and willingness to give written informed consent.
9. MMSE > 24
Exclusion Criteria:
1. Inability to read or speak English;
2. Documented disease of the central nervous system;
3. History of intellectual impairment pre-dating onset of symptoms of psychosis (e.g.
mental retardation);
4. Clinically significant or unstable cardiovascular, renal, hepatic, gastrointestinal,
pulmonary or hematological conditions;
5. HIV +;
6. Patients diagnosed with substance dependence;
7. Currently participating in another experimental study.
|
| NCT ID: |
|
NCT01036282 |
| Primary Contact: |
|
Principal Investigator
Jean-Pierre Lindenmayer, M.D.
Nathan S. Kline Institute for Psychiatric Research and Manhattan Psychiatric Center
Anzalee Khan, PhD
Email: AKhan@nki.rfmh.org
|
| Backup Contact: |
|
Email: manrtla@omh.state.ny.us
Theresa Abad, RN, MSN
|
| Location Contact: |
|
New York, New York 10605
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 21, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|